G1 Therapeutics, Inc. and Bionical Emas Launch Expanded Access Program for Trilaciclib in Small Cell Lung Cancer in the United States

G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage
oncology company, and Bionical Emas, a global specialist Clinical Research
Organization (CRO), today announced the launch of an Expanded Access Program (EAP) for trilaciclib, a first-in-class United States Food and Drug Administration (FDA) designated Breakthrough Therapy designed to improve the outcomes for people with cancer treated with chemotherapy. In June 2020, a New Drug Application (NDA) for trilaciclib was submitted to the FDA for myelopreservation in small cell lung cancer (SCLC). The FDA has granted Priority Review status with a Prescription Drug User Fee Act (PDUFA) date of February 15, 2021

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...